Kurma Miracle Drugs Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 26-12-2024
- Paid Up Capital ₹ 0.50 M
as on 26-12-2024
- Company Age 5 Year, 1 Month
- Last Filing with ROC 31 Mar 2024
- Revenue 14.24%
(FY 2022)
- Profit -33.59%
(FY 2022)
- Ebitda -29.90%
(FY 2022)
- Net Worth 2.65%
(FY 2022)
- Total Assets 38.23%
(FY 2022)
About Kurma Miracle Drugs
The Company is engaged in the Food And Beverages Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.50 M, as per Ministry of Corporate Affairs (MCA) records.
Rashim Mittal and Shweta Chauhan serve as directors at the Company.
- CIN/LLPIN
U24304PB2019PTC050318
- Company No.
050318
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
25 Nov 2019
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Chandigarh
Industry
Company Details
- Location
Patiala, Punjab, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Kurma Miracle Drugs Private Limited offer?
Kurma Miracle Drugs Private Limited offers a wide range of products and services, including Common Disease Medicines, Pharmaceutical Tablets, Nutraceuticals & Dietary Supplements, Vitamin & Multivitamin Injections, Medical & Surgical Clothing, Hospital Linen, Pharmaceutical Medicine, Pharma & Bioanalytical Services, PCD Pharma Franchise, Digestive System Drugs & Medicines.
Who are the key members and board of directors at Kurma Miracle Drugs?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rashim Mittal  | Director | 01-Sep-2023 | Current |
| Shweta Chauhan | Director | 25-Nov-2019 | Current |
Financial Performance of Kurma Miracle Drugs.
Kurma Miracle Drugs Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 14.24% increase. The company also saw a substantial fall in profitability, with a 33.59% decrease in profit. The company's net worth moved up by a moderate rise of 2.65%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Kurma Miracle Drugs?
Unlock access to Kurma Miracle Drugs's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Kurma Miracle Drugs?
Unlock and access historical data on people associated with Kurma Miracle Drugs, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Kurma Miracle Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Kurma Miracle Drugs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
